1. Home
  2. FUNC vs FULC Comparison

FUNC vs FULC Comparison

Compare FUNC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First United Corporation

FUNC

First United Corporation

SELL

Current Price

$43.81

Market Cap

282.0M

Sector

Finance

ML Signal

SELL

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

SELL

Current Price

$3.75

Market Cap

285.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FUNC
FULC
Founded
1900
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.0M
285.4M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
FUNC
FULC
Price
$43.81
$3.75
Analyst Decision
Buy
Hold
Analyst Count
2
5
Target Price
★ $50.00
$3.67
AVG Volume (30 Days)
27.9K
★ 1.4M
Earning Date
10-23-2026
10-28-2026
Dividend Yield
★ 2.60%
N/A
EPS Growth
★ 19.68
N/A
EPS
★ 1.90
N/A
Revenue
★ $18,426,000.00
N/A
Revenue This Year
$9.57
N/A
Revenue Next Year
$6.10
N/A
P/E Ratio
$22.84
★ N/A
Revenue Growth
★ 4.01
N/A
52 Week Low
$33.54
$2.83
52 Week High
$46.30
$15.74

Technical Indicators

Market Signals
Indicator
FUNC
FULC
Relative Strength Index (RSI) 50.32 47.37
Support Level $43.30 $3.62
Resistance Level $45.71 $3.91
Average True Range (ATR) 1.12 0.07
MACD 0.02 0.00
Stochastic Oscillator 45.13 37.50

Price Performance

Historical Comparison
FUNC
FULC

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: